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Few Zika virus (ZIKV) outbreaks had been reported since its first detection in 1947, until the recent 
epidemics occurred in South America (2014/2015) and expeditiously became a global public health 
emergency. This arbovirus reached 0.5-1.3 million cases of ZIKV infection in Brazil in 2015 and rapidly 
spread in new geographic areas such as the Americas. Despite the mild symptoms of the Zika fever, the 
major concern is related to the related severe neurological disorders, especially microcephaly in newborns. 
Advances in ZIKV drug discovery have been made recently and constitute promising approaches to 
ZIKV treatment. In this review, we summarize current computational drug discovery efforts and their 
applicability to discovery of anti-ZIKV drugs. Lastly, we present successful examples of the use of 
computational approaches to ZIKV drug discovery. 
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INTRODUCTION
Zika virus (ZIKV) is an arbovirus that belongs 
to genus Flavivirus, the same genus of Dengue virus 
(DENV), Yellow Fever Virus (YFV) and West Nile Virus 
(WNV) (Wahid et al., 2016). It was first isolated from 
rhesus monkeys in Uganda, Africa, in 1947 (Dick et al., 
1952). After the virus isolation, the disease did not call 
much attention because only a limited number of human 
infections were reported. The scenario changed after an 
outbreak in Micronesia in 2007 and epidemics in other 
areas across the Pacific (Duffy et al., 2009). In 2014 and 
2015 the virus spread increased dramatically in Americas, 
mostly in Brazil with an estimation of 0.5-1.3 million cases 
of ZIKV infection at the end of 2015 (Hennessey, Fischer, 
Staples, 2016). In 2016 the World Health Organization 
(WHO) declared the ZIKV as a global health emergency 
due to its quick dissemination and the connection with 
neuronal diseases (Gulland, 2016).
The typical symptoms of ZIKV disease are not 
very concerning like fever, joint pain, maculopapular 
rash, and conjunctivitis. However, the association of 
the disease with congenital microcephaly (Araújo et al., 
2016), Guillain-Barre syndrome (Oehler et al., 2014), and 
macular atrophy (Ventura et al., 2016) are the concerning 
aspects of the disease.
Currently, there are no specific vaccines or antiviral 
drugs available for the disease and many efforts have 
been made towards the development of new and effective 
antiviral compounds. Computational approaches have 
been used for ZIKV drug discovery with successful results. 
Besides the acceleration of the discovery process, these 
techniques reduce experimental costs, decrease the use 
of animals in experiments and are environment-friendly. 
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Here we review the computational techniques applied 
for the discovery of compounds that might stop ZIKV 
spreading.
COMPUTATIONAL TECHNIQUES APPLIED 
TO ZIKV DRUG DISCOVERY
The structural and biological knowledge about 
ZIKV is indisputably important for successfully guiding 
drug discovery projects. However, the infrastructure 
requirements for these experimental assays are beyond 
the reach of most researchers due to its high cost. To 
make experimental assays less expensive, researchers 
can use computer-assisted drug discovery (CADD) as 
a complementary approach to prioritize compounds for 
synthesis and/or biological evaluation. As no compound 
need be tested before computational simulations, CADD 
represents a time-, labor-, and cost-effective strategy to 
obtain antiviral compounds in the early stages of ZIKV 
drug discovery projects (Ekins et al., 2016b; Joy Macalino 
et al., 2015; Kar, Roy, 2013; Reynolds, 2014).
Typically, CADD approaches are applied in virtual 
screening (VS) campaigns. VS is often compared to a 
funnel, where thousands/millions of chemical structures 
(i.e., 105 to 107 compounds) available on virtual libraries 
are filtered by a computational model to a smaller set of 
potentially active chemicals (i.e., 101 to 103 compounds) 
that will then be synthesized and/or tested experimentally 
(Kar, Roy, 2013; Tanrikulu, Krüger, Proschak, 2013). 
Compared with typical hit rates from experimental 
approaches that can range between 0.01% and 0.14%, VS 
typically range between 1% and 40% (Zhu et al., 2013). 
Because of their obvious advantages, CADD approaches 
are widely employed in academic organizations and 
pharmaceutical industry. In the subsequent sections, we 
review current developments in CADD, highlighting main 
strategies and pitfalls that have implications in ZIKV drug 
discovery projects.
Ligand-based drug design (LBDD)
Usually, when the biological target is not known 
or its 3D structure is not available, CADD can use the 
chemical structures of known active compounds (i.e., 
obtained from biochemical or phenotypic assays) as 
starting points. This approach is known as Ligand-based 
drug design or LBDD (Glaab, 2016; Ripphausen, Nisius, 
Bajorath, 2011). There are four main LBDD methods: 
(i) similarity search; (ii) 3D shape matching; (iii) ligand-
based pharmacophores; and (iv) quantitative-structure 
activity relationships (QSAR).
Similarity search
Ligand similarity search is based on the principle 
that structurally similar compounds exhibit similar 
biological activities. Figure 1A shows the schematic 
representation of calculation of ligand-based similarity 
using Tanimoto coefficient and bit strings. As we can see, 
both known active compound and the database of untested 
compounds could be represented and further compared 
using molecular fingerprints, a high-dimensional sequence 
of bits that accounts for the absence (0) or presence (1) 
of representative fragments or atoms in each chemical 
structure (Cereto-Massagué et al., 2015; Gomes et 
al., 2017; Muegge and Mukherjee, 2016). Then, the 
comparison between bit vector sequences must be 
expressed using many similarity metrics. The most used 
metric to explore similarity is the Tanimoto coefficient, 
which is equal to the number of common bits set to 1 in 
both fingerprints divided by the total number of bits set 
to 1 between both fingerprints (Cereto-Massagué et al., 
2015; Gomes et al., 2017; Muegge, Mukherjee, 2016). 
It assumes that two structures with Tanimoto coefficient 
higher than 0.85 can be considered structurally similar 
(Cereto-Massagué et al., 2015; Neves et al., 2016).
Ligand-based pharmacophores and shape-based models
Ligand-based pharmacophores and shape-based 
models aim to identify potentially active compounds 
based on their overlapping to the 3D arrangement of key 
interacting chemical features (e.g., aromatic rings, hydrogen 
bond donors or acceptors, partial charges, etc.) or shape 
and volume of known active ligands not shared by inactive 
compounds (Figure 1B) (Caporuscio, Tafi, 2011; Hawkins, 
Skillmann, Nicholls, 2007; Vuorinen, Schuster, 2015). In 
the same way, 3D shape-based models identify potentially 
active compounds based on their overlapping to the 3D 
surface shape of active compounds (Figure 1B) (Hawkins, 
Skillman, Nicholls, 2007; Koes, Camacho, 2014; Kortagere, 
Krasowski, Ekins, 2009). The generation of both models 
basically involves four steps: (i) alignment of a training 
set of molecules (composed by actives and inactives) 
into a known bioactive query; (ii) scoring of compounds 
and selection of best pharmacophoric/shape hypothesis; 
(iii) statistical validation by using appropriate metrics to 
determine the ability of the hypothesis to discriminate 
between known active and inactive compounds (Braga, 
Andrade, 2013); and (iv) screening of untested compounds 
using the statistically validated models.
Quantitative Structure-Activity Relationships (QSAR)
One of the most popular approaches for computer-
aided drug design is the quantitative structure-activity 
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relationships (QSAR). QSAR is a method to quantify the 
correlation between the chemical structures of a set of 
compounds and a particular biological property (Gomes 
et al., 2017; Melo-Filho et al., 2016; Neves et al., 2016). 
QSAR modeling could be presented as three-part process 
(Figure 1C). Initially, chemical structures are converted into 
molecular descriptors (independent variables), which are the 
result of a logic and mathematical procedure that transforms 
chemical information into a useful number (Todeschini, 
Consonni, 2008). Then, machine learning methods (e.g., 
Random Forest (Breiman, 2001), Deep Learning (LeCun, 
Bengio, Hinton, 2015), Support Vector Machine (Vapnik, 
2000), etc.) are used to establish quantitative relationships 
between descriptors and biological property (dependent 
variable). This step involves empirically discovering a 
function that will establish weights to molecular descriptors 
adjusting the equation Bp = k’ (D1, D2,…,Dn), where 
Bp is biological property of molecules, D1, D2,…,Dn 
are molecular descriptors, and k’ is some empirically 
established weight assigned by the selected algorithm 
(Cherkasov et al., 2014; Tropsha, 2010). Lastly, the 
quality of the resulting QSAR model is measured by using 
appropriate metrics, which will check its ability to correctly 
predict the biological properties of experimentally evaluated 
compounds. Once validated, the generated model can be 
used in VS campaigns to prioritize untested compounds 
for synthesis and/or biological evaluation (Cherkasov et 
al., 2014; Tropsha, 2010).
FIGURE 1 - Schematic representation of LBDD methods. (A) calculation of chemical similarity using bit strings (encoded by the 
presence and absence of structural fragments) generated for a known active compound and a database of untested chemicals; (B) 
fitting of a compound into pharmacophore and shape-based models generated from a known active ligand. Hydrogen bond acceptors 
are represented as red spheres, respectively and aromatic rings by green spheres; and (C) QSAR modeling using machine learning 
approaches and multiple statistical metrics.
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ZIKV bioassays, such as cell viability (in human 
astrocyte, astrocytoma and neural progenitor cells) and 
quantitative High-Throughput Screening (qHTS), related 
to caspase-3 activity, in human astrocyte, astrocytoma 
and iPSC derived neural progenitor cells, have been 
performed and are available in PubChem, sourced by 
NCATS Chemical Genomics Center (NCGC). Therefore, 
from these bioassays, QSAR modeling could be utilized 
as a filter in Virtual Screening of hits against ZIKV.
Structure-based drug design (SBDD)
Structure-based drug design (SBDD) is a very useful 
approach when the biological target is known, and its 3D 
structure is available. Based on the target 3D structural 
information, SBDD methods can assist the selection of 
ligands with good complementarity and affinity to the 
protein binding site (Lionta et al., 2014). In early march 
2016, when the ZIKV outbreak started, there were no crystal 
structures for ZIKV proteins available and therefore there 
were several efforts to develop homology models based 
on close homologs such as DENV and others (Ekins et al., 
2016a). Currently, 49 entries containing 3D structures of 
ZIKV proteins are available in Protein Data Bank (PDB) 
(Berman et al., 2000). Based on that, SBDD strategies 
represents a promising tool for assisting with the discovery 
of new drugs against ZIKV. In general, SBDD methods 
can be divided in three main categories: (i) protein-ligand 
docking; (ii) structure-based pharmacophores; and (iii) 
molecular dynamics. These approaches are discussed below. 
Protein-ligand docking
Molecular docking is one of the most widely used 
SBDD methods, and largely applied in structure-based 
VS (SBVS) campaigns (Figure 2B). It consists of the 
computational fitting of ligands into the protein binding 
site, aiming to predict the ligand-protein complex, and 
estimating the ligand binding affinity (Ferreira et al., 
2015). In general, the docking process is executed in two 
main steps: (i) the exploration of the conformational space, 
by generating various poses (orientations) of the ligand, 
which is executed by the search algorithm; and (ii) the use 
of scoring functions to perform the ranking of the most 
promising ligand poses, and estimate the binding affinity 
(Kalyaanamoorthy, Chen, 2011). There is a variety of 
search methods for exploring the conformational space 
of ligands, such as systematic methods (conformational 
search, databases), random or stochastic methods (Monte 
Carlo, genetic algorithms), and simulation methods 
(energy minimization, molecular dynamics). The scoring 
functions are generally divided in three groups: force 
field-based, empirical, and knowledge-based functions 
(Kalyaanamoorthy, Chen, 2011; Kitchen et al., 2004; 
Lionta et al., 2014). 
Structure-based pharmacophores
Structure-based pharmacophore modeling takes 
advantage of the information about the 3D structure of 
proteins, and uses this information to probe interaction 
points between the protein and the ligand (Figure 2A) 
(Yang, 2010). There are two possibilities of calculating a 
SBP from a 3D protein structure: (i) The protein structure 
is complexed with a ligand (halo structure); and (ii) The 
protein has no complexed ligand (apo structure) (Pirhadi, 
Shiri, Ghasemi, 2013). In the first approach, the ligand 
binding site is identified, the key ligand-protein interactions 
are determined, and the gathered information is used to 
define the pharmacophore model (Yang, 2010). The second 
approach is based on the use of molecular probes (small 
fragments, functional groups) to map hot spots or possible 
interaction sites in the protein. These hot spots can be used 
as features, which are used to generate the pharmacophore 
model (Caporuscio, Tafi, 2011). The SBP approach can be 
used as a complement to docking studies, since it includes 
the same level of information. Furthermore, it demands 
less computational cost in comparison to docking, and 
represent a good alternative for researchers with limited 
computational resources (Braga, Andrade, 2013). 
Molecular dynamics simulations
Molecular dynamics (MD) simulations provide 
detailed information about the behavior of a system and its 
temporal evolution on a molecular scale (Salsbury, 2010). 
Through this technique, it’s possible to determine the 
motion of proteins and molecules, at atomic level, and the 
distinct interactions among them. The potential energy of 
interaction among atoms bonded (mainly including bond 
stretching, angle bending and dihedrals energies) or non-
bonded (including van der Waals and electrostatic energies) 
is used to determine the atom systems dynamic (Figure 2C). 
From the coordinates, initial position and initial velocities of 
the atoms, force and acceleration are calculated following 
Newton’s equations in order to obtain a temporal trajectory. 
MD simulations have become valuable tool in 
probing details of biomolecules dynamics. This approach 
allows sampling different protein conformations, 
exploring the energy landscapes of proteins, and 
understanding protein functions. MD is also relevant in 
drug discovery and development, specially used to study 
the effects of ligand binding on protein dynamics (Amato 
et al., 2012), and the protein conformations associated 
with specific cellular function to enable the discovery of 
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conformationally-selective ligands (Bernardes et al., 2013; 
Childers, Daggett, 2017; Mottin et al., 2017). Moreover, 
MD is useful in the structural refinements of post-docking 
complexes and in the analysis of protein-ligand complexes 
stability (G. Ricci et al., 2016; Musyoka et al., 2016; 
Ramharack, Soliman, 2018).
In silico drug repurposing 
The main aim of drug repurposing (or drug 
repositioning) is to identify new uses for already 
existing drugs (Baker et al., 2018; Ekins et al., 2011). 
This approach accelerates the drug discovery process, 
FIGURE 2 - Schematic representation of SBDD methods. (A) Structure-based pharmacophore model applied for VS of a large 
database of untested compounds. Yellow spheres represent hydrophobic features, red arrows are hydrogen bond acceptors, green 
arrow is a hydrogen bond donor feature, blue cone represents a metal interaction, and gray spheres are the exclusion volumes; (B) 
Ligand-protein docking applied for VS of a large database of untested compounds; and (C) Application of molecular dynamics 
simulations for insights of protein conformational changes, and the design of new anti-ZIKV drugs. 
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reducing time efforts and expenses, also circumvents 
preclinical development (March-vila et al., 2017). Recent 
drug repurposing experimental studies (Barrows et al., 
2016; Xu et al., 2016) demonstrated that screening 
approved or investigational drugs from datasets as FDA 
approved drugs, Library of Pharmacologically Active 
Compounds and NCATS pharmaceutical collection, is 
a promising strategy for identifying therapeutics with 
novel antiviral activity against ZIKV. Through this 
approach the following compounds have already been 
discovered as anti-ZIKV agents: niclosamide (Xu et al., 
2016), PHA-690509 (Xu et al., 2016), emricasan (Xu 
et al., 2016), seliciclib (Xu et al., 2016), bortezomib 
(Barrows et al., 2016), mycophenolic acid (Adcock et al., 
2017; Barrows et al., 2016), auranofin (Barrows et al., 
2016), ivermectin (Barrows et al., 2016) and daptomycin 
(Barrows et al., 2016). Today, only experimental HTS 
screening were performed for ZIKV drug repurposing, 
but in silico methods are also a promising approach for 
ZIKV drug repurposing and have been successfully 
applied in other examples (March-vila et al., 2017). This 
represents an opportunity that has been under-utilized 
for ZIKV. 
In silico fragment-based drug discovery (FBDD)
Fragment-Based Drug Discovery (FBDD) is a 
powerful computational technique to identify starting hits 
(small molecules or fragments) and then expand or link 
together to subsequent generate leads compounds (Mortier 
et al., 2012; Murray, Blundell, 2010; Zauhar, Gianti, 
Welsh, 2013). There are several strategies to perform 
fragment-based in silico approach, such as docking 
of fragment libraries; reapplication of de novo design 
programs to existing fragment collections; bioisosteric 
fragment replacement and pharmacophore screening for 
fragments (Mortier et al., 2012).
Since its development, a number of practical 
successful applications of FBDD have been reported in 
the literature for different targets (Mortier et al., 2012). 
Recently it has been used for DENV NS2B/NS3 protease 
(Frimayanti et al., 2012) and NS5 methyltransferase 
(Benmansour et al., 2017) proteins and represents a 
promising strategy for identifying hits for ZIKV. 
SUCCESSFUL APPLICATIONS COMPUTA-
TIONAL APPROACHES FOR ZIKV DRUG 
DISCOVERY
Virtual screening based on molecular docking has 
been used to select FDA-approved drugs, natural products 
and synthetic compounds for ZIKV non-structural 
proteins. The main focus of these VS are proteins involved 
in the viral replication complex process: NS3 helicase 
(Byler, Ogungbe, Setzer, 2016; Sahoo et al., 2016), 
NS5 RNA polymerase (Byler, Ogungbe, Setzer, 2016; 
Ramharack, Soliman, 2017) and NS5 methyltransferase 
(Byler, Ogungbe, Setzer, 2016; Ramharack, Soliman, 
2017). NS2B/NS3 protease is also an important target due 
to its role in preprocessing the viral polyprotein (Byler, 
Ogungbe, Setzer, 2016; Lee et al., 2016; Sahoo et al., 
2016). However, most of the published VS works do not 
validate their predictions with experimental assays, apart 
from one (Lee et al., 2016), which is a fundamental step 
to identifying new drug candidates.
One successful application of VS for ZIKV drug 
discovery has been performed in a collaboration with IBM 
World Community Grid (WCG) and some Universities/
Companies from Brazil and United States of America. This 
initiative, called the OpenZika project, is a collaborative 
open science project that virtually screens millions of 
compounds against all the ZIKV protein structures, 
through molecular docking and QSAR modelling (Figure 
3). The OpenZika main goal is to accelerate the drug 
discovery for ZIKV, creating a net of volunteers computers 
that help scientific calculations (Ekins et al., 2016c). These 
results are publicly available, helping other researchers to 
focus on the most likely compounds that may eventually 
lead to a ZIKV antiviral. The docking calculations have 
been made for the main ZIKV proteins NS1, NS2B-NS3 
protease, NS3 helicase and NS5 polymerase. From the 
beginning of the project (May 2016) until January 2018, 
~ 4.5 billion dockings have been submitted in WCG 
and ~ 3 billion results have been received. Many of the 
virtually selected compounds have been selected for 
experimental validation.
The first published result of this project is related 
to ZIKV NS3 helicase, which is the main component of 
the replication complex of the virus. Helicase displays 
nucleoside 5′-triphosphatase (NTPase) and 5′-terminal 
RNA triphosphatase (RTPase) activities. The dynamic 
behavior of ZIKV helicase was firstly studied through 
molecular dynamics (MD) simulations by the OpenZika 
team (Mottin et al., 2017). This approach showed that a 
region near the RNA binding site, known as RNA binding 
loop, is influenced by the presence of the RNA strand, 
being more stable in this case. The analysis of different 
enzyme conformations, through the AutoLigand program 
(Forli et al., 2016; Harris, Olson, Goodsell, 2008), 
showed a region beneath/behind the ATP site that perhaps 
represents an allosteric site, and may could help the design 
of a more specific inhibitor for ATP site.
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SUMMARY
ZIKV virulence and its devastating consequences to 
humans requires that we quickly discover new antivirals 
to stop this virus. This brief review highlights the 
computational technologies that are readily available to 
academia and industry, including both LBDD and SBDD. 
These have the potential to accelerate the process of drug 
discovery for ZIKV. We emphasize that, parallel to the 
computational strategies, it is important to perform the 
experimental validation and that there is a considerable 
opportunity for computational drug repurposing.
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